Vor Biopharma Reports Reduced Net Loss of $62.8 Million in Q2 2026

Vor Biopharma Inc. reported significant financial results for the second quarter of 2026, revealing a net loss of $62.8 million, a substantial decrease from the $1.57 billion loss recorded in the same period of 2025. For the first half of 2026, the company reported a net loss of $282.4 million, down from $1.61 billion in the prior year. The reduction in losses is attributed to a decrease in research and development expenses, which fell to $25.9 million in Q2 2026 from $261.5 million in Q2 2025, primarily due to a one-time expense of $222.6 million related to the Telitacicept License Agreement recognized in the previous year.

Vor Biopharma's total operating expenses for the second quarter of 2026 were $47.9 million, significantly lower than the $274.3 million reported in the same quarter of 2025. The decrease in expenses was driven by reduced research and development costs, alongside an increase in general and administrative expenses, which rose to $21.9 million from $12.8 million, largely due to higher stock-based compensation and commercial-related expenses. The company’s accumulated deficit as of June 30, 2026, stood at $1.44 billion, reflecting its ongoing investment in product development.

In terms of operational developments, Vor Biopharma is advancing its lead product candidate, telitacicept, which is currently undergoing a global Phase 3 clinical trial for the treatment of generalized myasthenia gravis (gMG). The trial is actively recruiting patients across multiple regions, including North America, Europe, and Asia, with topline data expected in the first half of 2027. The company is also evaluating telitacicept for Sjögren’s disease, with the first patient dosed in March 2026. Vor Biopharma's strategic focus on these clinical trials is expected to drive future growth and potential revenue generation.

As of June 30, 2026, Vor Biopharma reported cash, cash equivalents, and marketable securities totaling $466.1 million, which the company anticipates will fund its operations into early 2029. The company has also engaged in various financing activities, including a private placement in March 2026 that raised $74.9 million. Following the end of the reporting period, Vor Biopharma sold additional shares under its at-the-market sales agreement, generating gross proceeds of $48.9 million. The company continues to seek additional funding to support its ongoing clinical trials and operational needs, emphasizing the importance of securing capital to sustain its growth trajectory.